MedTrace Logo

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

NCT01381705 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 259

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma.

Conditions

Interventions

BIOLOGICAL

rituximab

GENETIC

DNA analysis

GENETIC

gene expression analysis

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

OTHER

medical chart review

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Brad S. Kahl, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-06
Primary Completion
2012-07-06
Completion
2012-07-06

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381705 on ClinicalTrials.gov